NEW YORK (Reuters Health) Jul 19 –
The new calcium sensitizer levosimendan is better than dobutamine at improving hemodynamic performance in patients with severe low-output heart failure, according to a report published in the July 20th issue of The Lancet.
Unlike dobutamine, the authors explain, levosimendan does not act through adrenergic pathways and, therefore, does not cause diastolic calcium overload–which can increase energy expenditure, impair myocardial relaxation, or both.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!